Title
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.

Permalink
https://escholarship.org/uc/item/3sr8b500

Journal
Leukemia research reports, 3(2)

ISSN
2213-0489

Authors
Goldberg, Stuart L
Fenaux, Pierre
Craig, Michael D
et al.

Publication Date
2014

DOI
10.1016/j.lrr.2014.06.003

Peer reviewed
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

Stuart L. Goldberg, Pierre Fenaux, Michael D. Craig, Emmanuel Gyan, John Lister, Jeannine Kassis, Arnaud Pigneux, Gary J. Schiller, JungAh Jung, E. Jane Leonard, Howard Fingert, Peter Westervelt

A John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA
B Service d’hématologie Clinique, Hôpital Avicenne (AP-HP)/Université, Paris 13, Bobigny, France
C Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown, WV, USA
D Service d’hématologie et Thérapie Cellulaire, CNRS UMR 7292, CHRU de Tours, France
E Division of Hematology and Cellular Therapy, Western Pennsylvania Cancer Institute, Pittsburgh, PA, USA
F Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada
G Service d’hématologie CHU Bordeaux, Pessac, France
H David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
I Takeda Pharmaceuticals International Co., Cambridge, MA, USA
J Division of Oncology, Washington University Medical School, St. Louis, MO, USA

ARTICLE INFO

Article history:
Received 19 November 2013
Received in revised form 6 June 2014
Accepted 14 June 2014
Available online 5 July 2014

Keywords:
Aurora A kinase inhibitor
Alisertib
Safety
Acute myeloid leukemia (AML)
Myelodysplastic syndrome (MDS)

Abstract

Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% response rate with an additional 49% stable disease, 34% transfusion independence) included 1 complete response lasting > 1 year. No responses were observed in MDS patients. Adverse events > 30% included diarrhea, fatigue, nausea, febrile neutropenia, and stomatitis. Results suggest modest activity in AML, supporting further research to better understand how AAK inhibition may induce leukemic cell senescence.

© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

The Aurora kinases are serine/threonine protein kinases essential for regulation of normal cell cycle mitosis. Aurora kinases A (AAK) and B are overexpressed in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); reduction of intracellular AAK results in mitotic inhibition, senescence, and apoptosis in human cell lines [1].

Alisertib (MLN8237) is an investigational, orally available, selective, small-molecule AAK inhibitor [1] with antitumor activity in preclinical leukemia models [2,3].

Here we report an exploratory phase 2 trial of alisertib in a heterogeneous patient population with AML or high-grade MDS (NCT00830518). The single-agent alisertib regimen administered in this study was determined by prior phase 1 studies [4,5].

2. Methods

AML patients ineligible for potentially curative treatment options, with > 10% bone marrow (BM) or peripheral blood blasts at relapse, and who had failed to achieve complete response (CR) or relapsed after prior therapy were eligible. High-grade MDS patients were defined as follows: (a) International Prognostic Staging System (IPSS) risk Intermediate-2 or High; (b) > 10% BM blasts; and (c) treatment failure from, or not a candidate for, standard therapies. Patients were aged ≥ 18 years, with ECOG performance status 0–2, and adequate hepatic and renal function.

The study was conducted according to the Declaration of Helsinki and Good Clinical Practice. Review boards at all participating institutions approved the study protocol and all patients provided written informed consent.
In this open-label, phase 2 study, conducted in the USA, Canada, and France, patients received alisertib 50 mg BID for 7 days plus 14-days' rest in 21-day cycles until disease progression or unacceptable toxicity.

Response was evaluated per AML and MDS International Working Group (IWG) criteria [6,7]. Primary endpoint was overall response rate (ORR; CR plus partial response [PR]). ‘CR’ included CR with incomplete blood count recovery (per IWG guidelines) in AML patients and marrow CR in MDS patients; ‘PR’ included incomplete blood count recovery in AML and MDS patients [6,7]. Secondary endpoints included progression-free survival (PFS), duration of response (DOR), and hematologic improvement in MDS patients. The response-evaluable population for the primary endpoint analysis included patients who received ≥1 post-baseline response assessment. Safety and tolerability were monitored throughout. Adverse events (AEs) were graded by NCI CTCAE v3.0. The safety population included patients who received ≥1 dose of alisertib and had ≥1 post-baseline response assessment.

A Simon optimal 2-stage design was used, with 21 patients enrolled in the first stage and ≥2 responses required to proceed to the second stage. Sample size was estimated using a 1-sided test at the significance level of α = 0.05, power of 90%, a null hypothesis of response rate ≤5%, and an alternative hypothesis of response rate ≥20%. To obtain 41 response-evaluable patients, enrollment of ~44 patients was projected. Time-to-event data were analyzed by Kaplan–Meier methodology.

3. Results

Fifty-seven patients were enrolled (Table 1). The median number of treatment cycles received was 2 (range 1–26) with similar medians for AML and MDS. The maximum number of cycles received for AML and MDS patients was 26 and 6, respectively, with differences between diseases driven by an increased response rate in AML patients.

Forty-five patients were response-evaluable; 12 were not due to lack of on-study response assessment. ORR for the study was 13% (response-evaluable patients). Two responses were documented in stage 1; therefore, the study continued to stage 2. Recruitment continued beyond the expected 44 patients in order to enroll 8 MDS patients.

3.1. Response – AML

Thirty-five AML patients were response-evaluable; 6 responded (CR, n = 1; PR, n = 5; Table 2) giving an ORR of 17%. Four of the 6 responders had a history of prior MDS. DORs for responders were 21* [asterisks denote censored observations], 27*, 57, 91*, 409, and 596 days, respectively, including 1 patient with durable CR through 16 cycles (~1 year). Seventeen patients (49%) had stable disease. Time to first response was 1–4 cycles. Changes in blasts in responding patients shown in Fig. 1. There was no apparent pattern of response according to AML subtype based on the IWG recommended classifications (Table 2).

Twelve of 35 AML patients (34%) achieved transfusion independence during the study; 10 maintained independence for ≥2 cycles, and 1 for ≥4 cycles.

Median PFS was 55 days (95% CI: 47, 67 days; range 1*–638).

Table 1

| Patient demographics and baseline characteristics. | AML | MDS | Total |
|-----------------------------------------------|-----|-----|-------|
| n (%) (n = 46) | n (%) (n = 11) | n (%) (N = 57) |
| Median age, years (range) | 72 (48–83) | 72 (46–85) | 72 (46–85) |
| Male | 24 (52) | 8 (73) | 32 (56) |
| White | 36 (78) | 10 (91) | 46 (81) |
| Primary disease* | 25 (54) | 10 (91) | 35 (61) |
| Secondary disease | 21 (46) | 1 (9) | 22 (39) |
| Prior history of MDS | 18 (39) | – | 36 (63) |
| IPSS score | – | – | – |
| Intermediate-2 (1.5 or 2.0) | – | 8 (73) | – |
| High (≥2.5) | – | 3 (27) | – |
| ECOG PS 0/1/2, n | 9/29/8 | 3/8/0 | 12/37/8 |
| Extramedullary disease | 3 (7) | 0 | 3 (5) |
| Median time since diagnosis, years | 0.31 | 0.50 | 0.33 |

Classification of AML

| AML with recurrent genetic abnormalities | 1 (2) | – | – |
| AML with multilineage dysplasia | 21 (46) | – | – |
| AML therapy-related | 3 (7) | – | – |
| AML not otherwise categorized | 24 (52) | – | – |
| AML minimally differentiated | 4 (9) | – | – |
| AML without maturation | 1 (2) | – | – |
| AML with maturation* | 11 (24) | – | – |
| Acute myelomonocytic leukemia | 4 (9) | – | – |
| Acute erythroid leukemia | 1 (2) | – | – |
| Acute megakaryoblastic leukemia | 1 (2) | – | – |
| Other | 2 (4) | – | – |

Prior therapy | 39 (85) | 10 (91) | 49 (86) |

Azacitidine | 19 (41) | 6 (55) | 25 (44) |
Cytarabine | 22 (48) | 3 (27) | 25 (44) |
Decitabine | 14 (30) | 4 (36) | 18 (32) |
Idarubicin | 12 (26) | 1 (9) | 13 (23) |
Allogeneic/autologous transplant | 3 (7) | 0 | 3 (5) |
Radiation therapy | 2 (4) | 1 (9) | 3 (5) |
≥3 prior therapies | 8 (17) | 1 (9) | 9 (16) |

Best response to prior therapy (n) | 39 | 10 | 49 |

CR | 9 (23) | 1 (10) | 10 (20) |
PR | 4 (10) | 0 | 4 (8) |
SD | 11 (28) | 2 (20) | 13 (27) |
Median time since progression, months | 1.3 | 1.0 | 1.1 |

AML, acute myeloid leukemia; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; IPSS, International Prognostic Staging System; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; PR, partial response; and SD, stable disease.

* Modified World Health Organization criteria at the time of primary diagnosis.

Table 2

| Investigator-assessed best response in response-evaluable patients receiving alisertib. | AML | MDS | Total |
|-----------------------------------------------|-----|-----|-------|
| n (%) (n = 35) | n (%) (n = 10) | n (%) (N = 45) |
| ORR (CR+PR) | 6 (17) | 0 | 6 (13) |
| CR | 1 (3)* | 0 | 1 (2) |
| PR | 3 (14)* | 0 | 5 (11) |
| SD | 17 (49) | 2 (20) | 19 (42) |

AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete response; PR, partial response; and SD, stable disease.

* The patient with CR had AML with multilineage dysplasia.

Table 2

| Investigator-assessed best response in response-evaluable patients receiving alisertib. | AML | MDS | Total |
|-----------------------------------------------|-----|-----|-------|
| n (%) (n = 35) | n (%) (n = 10) | n (%) (N = 45) |
| ORR (CR+PR) | 6 (17) | 0 | 6 (13) |
| CR | 1 (3)* | 0 | 1 (2) |
| PR | 3 (14)* | 0 | 5 (11) |
| SD | 17 (49) | 2 (20) | 19 (42) |

AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete response; PR, partial response; and SD, stable disease.

* The patient with CR had AML with multilineage dysplasia.

** 5 patients with PR had AML with multilineage dysplasia (n = 2), or AML not otherwise categorized (n = 3) which included acute myelomonocytic leukemia (n = 1), acute megakaryoblastic leukemia (n = 1), and other: post-MDS (n = 1).

Two patients transformed from MDS to AML during the study – 1 patient transformed before the first response assessment (counted as AML), and the other transformed at the second response assessment (counted as MDS).
3.2. Response – MDS

None of 10 response-evaluable MDS patients responded; 1 patient achieved transfusion independence, maintained for at least 2 cycles.

Median PFS was 38 days (95% CI: 35, 113; range 22°–113).

3.3. Safety

All patients experienced ≥ 1 AE (Table 3). Drug-related grade ≥ 3 AEs were reported in 26 patients (46%; n=19 AML, n=7 MDS). Serious AEs were documented in 44 patients (77%; drug-related in n=15, 26%). Fourteen patients (25%) discontinued due to AEs.
There were 22 on-study deaths (20 AML; 2 MDS), including 10 deaths prior to cycle 2. All deaths were considered unrelated to alisertib; causes were progressive disease (n=10, 46%), sepsis (n=5, 23%), cerebral/intracranial hemorrhage (n=2, 9%), gastrointestinal infection, multi-organ failure, respiratory failure, renal failure, and subdural hematoma (each n=1, 5%).

4. Discussion

These results suggest that alisertib has modest single-agent anti-leukemic activity, demonstrating a 13% ORR. Six responses (17% ORR) were observed among AML patients, all of whom had pre-treated disease. An additional 49% of AML patients achieved stable disease, indicating a potentially clinically beneficial effect. Responses were generally observed by cycle 4 rather than during cycle 1, suggesting that, in the absence of disease progression, multiple cycles may be necessary to achieve anti-leukemic activity. Overall median PFS in this study was 51 days.

The population in this exploratory phase 2 trial primarily consisted of patients with progressive disease, including 21 patients (43%) refractory to most recent prior therapy and 3 having failed prior transplant (2 allogeneic). Improved clinical outcomes with alisertib may be possible in more selected populations, such as those without refractory disease and those robust enough to receive adequate drug to be effective.

The lack of response in MDS patients compared with AML patients may point to important clues in alisertib clinical mechanism of action. Failure of hematopoiesis in MDS is principally driven by increased apoptosis in the malignant clone, in contrast to narrow suppression by a proliferative clone in AML. In-vitro studies have shown that reduction of intracellular AAK results in mitotic inhibition, senescence, and apoptosis in human cell lines [1]. Thus, alisertib may be unable to stimulate an apoptotic clone in MDS but may suppress a proliferative clone in AML.

Transfusion independence was achieved in 13 patients and maintained for 2–5 cycles in 11 patients, suggesting that recovery of normal hematopoiesis can occur. Additional studies are needed to identify predictors of response and to understand how AAK inhibition may induce leukemia cell senescence, a property described with preclinical model systems [8], which may complement an antimitotic effect. In conclusion, alisertib demonstrated modest single-agent anti-leukemic activity, mostly limited to AML patients in this study. The toxicity profile was generally acceptable, and consistent with expected effects of Aurora kinase inhibition in proliferative tissues [9,10]. To allow for potentially delayed treatment effects by alisertib, improved clinical outcomes in larger populations will likely require additional strategies to enable early disease control. Results of this study of alisertib in AML/MDS highlight the need to develop predictors of response, combination regimens, and other strategies to enhance the clinical utility of treatment with this novel AAK inhibitor.

Role of the funding source

Research funded by Takeda Pharmaceuticals International Co.; alisertib was manufactured and supplied by Takeda Pharmaceutical International Co. The sponsor declares a role in the study design, collection and analysis of data, as reflected by the inclusion of company authors. The final decision to submit the manuscript for publication lay solely with the authors.

Contributions

SLG, PF, MDC, EG, JL, JK, AP, GJS, and PW recruited and treated patients. JL, EJL, and HF participated in study design and data collation. All authors participated in the preparation of the manuscript and approval of the final version to be submitted.

Conflicts of interest

Employment: HF, EJL, JJ (Takeda Pharmaceuticals International Co.). Research Funding: SLG (Millennium: The Takeda Oncology Company); EG (Amgen, Janssen-Cilag, Celgene); GJS (Millennium: The Takeda Oncology Co.); PF (Celgene, Janssen-Cilag, Amgen, Roche, GSK, Novartis, Merck, Cephalon).

Honoraria: EG (Janssen, Celgene); PW (Novartis, speakers bureau); PF (Celgene, Janssen-Cilag, Amgen, Roche, GSK, Novartis, Merck, Cephalon).

Membership: MDC (Genentech).

AP, JK, JL have no conflicts of interest to disclose.

Acknowledgments

The authors would like to thank the patients who participated in this study and their families. The authors would also like to acknowledge the writing assistance of Stephen Mosley, Ph.D., of Knowledge Point 360, in the development of this manuscript, which was funded by Millennium: The Takeda Oncology Company, and Jeff Klko, MD, for providing photomicrographs.

References

[1] Manfredi MG, Ecsedy JA, Meece KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106–11.
[2] Kelly KR, Ecsedy J, Medina E, Mahalingham D, Padmanabhan S, Nawrocki ST, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 2011;15:2057–70.
[3] Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang J, Padmanabhan S, et al. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer 2012;131:2693–703.
[4] Cervantes A, Elez E, Roda D, Ecsedy JA, Macarulla T, Venkatakrishnan K, et al. Phase I pharmacokinetic/pharmacodynamic study of MLN8237 – an investigational, oral, selective, Aurora A Kinase inhibitor – in patients with advanced solid tumors. Clin Cancer Res 2012;18:4764–74.
[5] Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, et al. Phase I study of Aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012;18:4775–84.
[6] Cheson BD, Bennett JM, Kopecny KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642–9.
[7] Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–25.
[8] Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585–98.
[9] Boss DS, Beijnen JH, Schelens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist 2009;14:780–93.
[10] Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors – rising stars in cancer therapeutics. Mol Cancer Ther 2010;9:268–78.